# OnCo record nct04106492 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04106492/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04106492", "NCT04106492" ;
  schema:name "SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a)"@en ;
  schema:alternateName "SQ3370-001"@en, "Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors"@en ;
  schema:description "Described by its investigators as the first use of click chemistry inside patients. A gel was injected into one tumour and an inactive form of doxorubicin was given into a vein, to be switched on at the gel. Doses far above the usual doxorubicin dose were tolerated, but tumours shrank in 2 of 14 sarcoma patients, no more often than with ordinary doxorubicin, and the sponsor stopped the trial."@en ;
  schema:url <https://onco.cc/trials/nct04106492/> ;
  schema:dateModified "2026-11-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04106492>, <https://clinicaltrials.gov/study/NCT04106492?tab=results>, <https://doi.org/10.1101/2025.06.02.25328445>, <https://doi.org/10.1158/1078-0432.CCR-24-2539>, <https://doi.org/10.1200/JCO.2024.42.16_suppl.11555> ;
  onco:status "mixed" ;
  onco:tag "failure" ;
  onco:phase "1/2" ;
  schema:startDate "2020-08-01" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/click-activated-prodrugs/> ;
  onco:drugs <https://onco.cc/drugs/sq3370/> ;
  onco:companies <https://onco.cc/companies/shasqi/> ;
  onco:institutions <https://onco.cc/institutions/sarcoma-oncology-center/>, <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/city-of-hope/>, <https://onco.cc/institutions/chris-obrien-lifehouse/> ;
  onco:terms <https://onco.cc/terms/rp2d/>, <https://onco.cc/terms/dose-limiting-toxicity/>, <https://onco.cc/terms/orr/> ;
  onco:people <https://onco.cc/people/sant-chawla/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025/>, <https://onco.cc/key-papers/paper-srinivasan-sq3370-preclinical-to-first-in-human-clin-cancer-res-2025/> .
